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The demonstration of beneficial eﬀects of cell therapy despite the persistence of only few transplanted cells in vivo suggests secreted
factors may be the active component of this treatment. This so-called paracrine hypothesis is supported by observations that
culture media conditioned by progenitor cells contain growth factors that mediate proangiogenic and cytoprotective eﬀects.
Cardiac progenitor cells in semi-suspension culture form spherical clusters (cardiospheres) that deliver paracrine signals to
neighboring cells. A key component of paracrine secretion is exosomes, membrane vesicles that are stored intracellularly in
endosomal compartments and are secreted when these structures fuse with the cell plasma membrane. Exosomes have been
identified as the active component of proangiogenic eﬀects of bone marrow CD34+ stem cells in mice and the regenerative eﬀects
of embryonic mesenchymal stem cells in infarcted hearts in pigs and mice. Here, we provide electron microscopic evidence of
exosome secretion by progenitor cells in mouse myocardium and human cardiospheres. Exosomes are emerging as an attractive
vector of paracrine signals delivered by progenitor cells. They can be stored as an “oﬀ-the-shelf” product. As such, exosomes have
the potential for circumventing many of the limitations of viable cells for therapeutic applications in regenerative medicine.
1. Introduction
Myocardial infarction and ensuing heart failure are the lead-
ing cause of mortality inWestern countries. Infarction causes
a massive loss of cardiomyocytes, which are replaced by scar
tissue. To compensate for lost contractile cells, the remaining
cardiomyocytes undergo hypertrophy and the heart remod-
els. These adaptive mechanisms are detrimental in the long
run, eventually leading to congestive heart failure. Heart
transplantation remains the ultimate treatment for chro-
nic heart failure; however, this approach is limited by donor
organ shortage, graft rejection, and the need for life-long
immunosuppression.
Over the past decade, cell transplantation has been evalu-
ated as a novel approach for heart failure. An early study
reported that adult mouse bone marrow (BM) hematopoi-
etic stem cells (HSCs) injected into infarcted mouse hearts
diﬀerentiated into cardiomyocytes and improved cardiac
function [1]. This report sparked widespread enthusiasm for
BM cell transplantation as a potential approach for repair-
ing broken hearts. Several subsequent studies failed to con-
firm the ability of HSCs to transdiﬀerentiate into cardiomy-
ocytes [2, 3]. However, these negative results did not prevent
clinical studies of autologous BM stem cell transplantation
for cardiac regeneration from being initiated [4–9]. Multiple
types of stem and progenitor cells, including embryonic
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stem cells (ESCs), adult skeletal myoblasts, adult BM-derived
mononuclear cells, purified BM-derived subpopulations
(e.g., c-kit+ and CD133+), and BM or adipose-derived mes-
enchymal stem cells (MSCs) have been evaluated as cell
sources for heart cell therapy [10, 11].
Almost ten years after the initiation of randomized, con-
trolled clinical trials of cell therapy for cardiac regeneration,
it must be recognized that results have been inconsistent, and
the overall improvement of cardiac function in patients after
myocardial infarction (MI) has been modest [12–14]. The
optimal timing of cell transfer, dose, delivery technique, the
mechanism of action, patient selection, cell retention, and
cell survival after transplantation are poorly understood. In
addition, impaired cell functionality in old patients and in
those with advanced cardiovascular disease or comorbidi-
ties limits autologous cell transplantation [15]. Hence, an
unresolved paradox persists between robust benefits of cell
therapy in animal models and modest eﬀects in patients.
Transdiﬀerentiation of adult BM cells into cardiomy-
ocytes has not been demonstrated in humans. Originally
proposed as an approach for providing injured hearts with
new cells capable of restoring contractile function in scar
areas, the biological rationale of cell therapy has progressively
shifted toward beneficial eﬀects mediated by transplanted
cells on neighboring cells, possibly including the stimu-
lation of endogenous regenerative mechanisms. Increasing
evidence suggests cell therapy, whether myoblast or BM cell-
based, may act by increasing the cellular mass in the infarcted
area, thereby reducing ventricular remodeling, and by pre-
venting cardiomyocytes in the ischemic peri-infarct zone
from dying. The second mechanism, which involves secreted
factors, has been referred to as the “paracrine hypothesis.”
Growth factors and cytokines secreted by transplanted cells
activate endogenous intracellular signaling pathways poten-
tially resulting in improved survival of endogenous cells and
formation of new blood vessels [16–18].
2. Adult Cardiac Stem Cells (CSCs) Expressing
Stem Cell Surface Markers
The adultmyocardium is a highly organized tissue comprised
of multiple cell types, including cardiomyocytes, endothelial
cells, vascular smooth muscle cells, multiple types of inter-
stitial cells, and extracellular matrix (ECM), which form a
cardiovascular unit [19]. Interstitial cells include cardiac-
resident stem and progenitor cells (CSCs) located within
stem cell niches [20]. These niches contain particular ECM
components, supporting cells, nerves, and blood vessels.
Several groups have isolated and characterized bona fide adult
CSCs from rodents and humans [21–29]. Molecular markers
that have been used to identify CSC populations include
cell-surface epitopes expressed on stem cells in other tis-
sues, particularly on HSCs, such as c-kit (CD117; the recept-
or for stem cell factor) and stem cell antigen-1 (Sca-1). At
minimum, five seemingly diﬀerent populations of CSCs have
been described [30]. Whether these populations represent
distinct entities of CSCs or diﬀerent developmental stages or
activation states of a single entity of CSC remains unclear.
Likewise, the origin of CSCs has not been definitively
established. In this regard, we and others have shown that
BM-derived cells can acquire stem cell properties in the
damaged heart [31, 32].
It has been speculated that cells derived from the heart
itself may be a logical candidate cell source for repairing
this organ, as these cells might be intrinsically programmed
to support cardiac cell survival and function. In animal
models of MI, injection of in vitro expanded CSCs has been
associated with functional improvement [21–27]. However,
direct comparisons of CSCs with other cell sources are
needed in order to identify themost eﬀective cell type. Recen-
tly, novel approaches based on adult cell reprogramming
(induced pluripotent stem cells; iPS) have been developed
[33]. Although extremely promising, these strategies are still
associated with potential safety concerns. The discussion of
these modalities is beyond the scope of the present work (the
interested reader is referred to an excellent review published
elsewhere [34]).
3. Cardiospheres (CSs) and
CS-Derived Cells (CDCs)
First described in neural stem cells (neurospheres) [35],
“spheres” have been considered—or named, at least—a fea-
ture of stemness. However, spheres can result not only from
cell proliferation but also from cell aggregation, and therefore
be clonal or nonclonal, respectively. The proportion of clonal
spheres increases with decreasing cell density in a culture dish
[36].
First described by Messina et al. [37], “cardiospheres”
(CSs) are self-assembling spherical clusters of cells obtained
by outgrowth from cardiac explants in the primary ex vivo
tissue culture. CSs grow in semisuspension culture on poly-
D-lysine. They represent the best in vitro model of CSC
niche-like environment [38]. While undiﬀerentiated cells
proliferate in the core of the CS, cardiac-committed cells
grow on the periphery. We have generated CSs from the cel-
lular outgrowth from adult human atrial appendage explants
(Figure 1). The cellular outgrowth expressed MSC surface
markers (CD13+, CD73+, and CD105+) but not hematopoi-
etic markers (CD45−). In line with previous studies [25, 37],
we have demonstrated the expression of cardiac-specific
genes, such as troponin I, in human CSs (Figure 2). CSs
placed in a new culture dish disassembled and gave rise to a
monolayer of CS-derived cells (CDCs) that formed second-
generation CSs. CDCs could be expanded as monolayers on
fibronectin (Figure 1). Previous studies [25, 39] reported that
CDCs are clonogenic and have multilineage diﬀerentiation
potential. By contrast, a recent study in rodents questioned
the notion of CSs as a source of stem cells with cardio-
myogenic potential [40]. This study suggested spontaneously
beating CSsmay result from remnants of myocardial tissue in
the cellular outgrowth from cardiac explants. Regardless of
this issue, CDCs have been shown to improve left ventricular
ejection fraction (LVEF) in SCID beige mice 3 weeks after MI
when compared to mice injected with vehicle or with adult
normal human dermal fibroblasts [25]. These beneficial
eﬀects were associated with increased blood vessel formation
and decreased apoptosis [41].
Journal of Biomedicine and Biotechnology 3
0
0.2
0.4
0.6
0.8
100 101 102 103
CD105
0
1
0.5
100 101 102 103
CD13
CD73
0
0.2
0.4
0.6
0.8
100 101 102 103
0
20
40
60
80
100
100 101 102 103
CD45
Explant
CSs50 μm
CDC
Figure 1: Left and middle panels: Flow cytometric analysis of the cellular outgrowth from a human atrial appendage explant in the
primary tissue culture, showing MSC (CD13+, CD73+, and CD105+) but not hematopoietic (CD45−) marker expression. Upper right panel:
Photomicrograph of a human atrial explant with cellular outgrowth; middle right panel: human CSs; lower right panel: human CDCs.
Autologous c-kit+, diﬀerentiation lineage-negative
(Lin−) CSCs, as well as CDCs, have recently been tested
in initial clinical studies. These two clinical trials of CSC
therapy for cardiac repair are briefly discussed in the next
section.
4. Clinical Studies of Autologous CSCs for
Ischemic Heart Disease
The first clinical trial of autologous CSCs for ischemic heart
disease was the stem cell infusion in patients with ischemic
cardiomyopathy (SCIPIO) trial (registered with ClinicalTri-
als.gov, number NCT00474461) [42]. This phase-1 clinical
trial tested autologous c-kit+/Lin− CSCs for treatment of
heart failure resulting from ischemic heart disease. In stage
A of this trial, patients with reduced LVEF (≤40%) after
MI before coronary artery bypass grafting (CABG) were
consecutively enrolled in the treatment and control groups.
In stage B, patients were randomly assigned to the treatment
or control group. Autologous CSCs were administered by
intracoronary infusion at a mean of 113 days (SE 4) after
surgery. Sixteen patients were assigned to the treatment
group and seven to the control group. No cell therapy-related
adverse eﬀects were reported. In 14 CSC-treated patients who
were analyzed, LVEF increased from 30.3% (SE 1.9) before
CSC infusion to 38.5% (SE 2.8) at 4 months after infusion
(P = 0.001). Conversely, in seven control patients LVEF did
not change during the corresponding time interval (30.1%
[SE 2.4] at 4 months after CABG versus 30.2% [SE 2.5] at
8 months after CABG). In eight treated patients studied at 1
year, LVEF increased by 12.3 LVEF units [SE 2.1] versus base-
line (P = 0.0007). These results suggest intracoronary infu-
sion of autologous c-kit+/Lin− CSCsmay enhance LV systolic
function in patients with heart failure after MI. In the
seven treated patients in whom cardiac magnetic resonance
imaging (MRI) was done, infarct size decreased from 32.6 g
(SE 6.3) by 7.8 g (SE 1.7; 24%) at 4 months (P = 0.004) and
9.8 g (SE 3.5; 30%) at 1 year (P = 0.04). This reduction in
scar is diﬃcult to interpret due to the lack of MRI data in the
control group.
The prospective, randomized CArdiosphere-Derived
aUtologous stem CElls to reverse ventricUlar dySfunc-
tion (CADUCEUS) trial (registered with ClinicalTrials.gov,
NCT00893360) evaluated autologous CDCs in patients with
reduced LVEF (=25–45%; mean baseline value =39%; [SD
12]) 2–4 weeks after AMI [43]. Seventeen patients received
CDCs and eight patients were randomized to the con-
trol group. Autologous CDCs grown from endomyocardial
biopsy specimens were infused into the infarct-related artery
1.5–3 months after MI. Biopsy samples yielded the pre-
scribed cell doses within 36 days (SD 6). By 6 months,
no patients had died, developed cardiac tumors, or major
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Figure 2: Immunostaining of a human CS showing expression of cardiac troponin I (red); nuclei stain blue.
adverse cardiac events in either group. Four patients (24%)
in the CDC group had serious adverse events compared
with one control (13%; P = 1.00). MRI analysis showed
reductions in scar mass by 28% by 6 months and 42% by
12 months (P = 0.001), increases in viable heart mass by
13.0 g at 6 months (P = 0.01), greater regional contractility
(−11.8% versus −8.5%; P = 0.02), and regional systolic
wall thickening (P = 0.015) in the CDC group compared
with controls. Changes in end-diastolic volume, end-systolic
volume, and LVEF did not diﬀer between groups by 6
months. These results suggest that intracoronary infusion
of autologous c-kit+/Lin− CSCs or CDCs after myocardial
infarction is safe andmight be beneficial. Larger clinical trials
to test the eﬃcacy of these approaches are being planned.
5. Paracrine Effects of Transplanted Cells
Based on the number of human-specific cells relative to
overall increases in capillary density andmyocardial viability,
Chimenti et al. [41] estimated that direct progenitor cell dif-
ferentiation quantitatively accounted for 20% to 50% of
the observed eﬀects of human CDCs transplanted into
infarcted SCID mouse hearts. Conversely, a large part of
these eﬀects seemed attributable to endogenous cells. In
vitro, culture media conditioned by human adult CDCs pre-
vented apoptosis in neonatal rat ventricular myocytes under
hypoxic conditions, while promoting angiogenesis from
human umbilical vein endothelial cells (HUVECs). In vivo,
human CDCs secreted hepatocyte growth factor-1 (HGF-1),
insulin-like growth factor-1 (IGF-1), and vascular endothe-
lial growth factor (VEGF) when transplanted into the same
SCID mouse model of MI, where they were shown to induce
tissue regeneration and improve function. Injection of CDCs
into the peri-infarct zone increased the expression of the
prosurvival factor Akt, reduced apoptosis, and increased
capillary density. Although myocardial perfusion was not
directly measured in this study, increased capillary density
was consistent with a role for angiogenesis in functional
improvement. These findings were interpreted as evidence
for paracrine eﬀects of CDCs exceeding those of direct
regeneration. In another study, Tang et al. [44] reported
beneficial eﬀects of paracrine factors secreted by rat c-kit+
CSCs delivered by intracoronary infusion 4 weeks after MI.
Although no engrafted donor cells were found in some hearts
in the cell therapy group, scar area was reduced and cardiac
output increased compared with the control group. The
number of cardiomyocytes, blood vessels, and endogenous
cardiac progenitor cells was increased in hearts injected
with c-kit+ CSCs, even in the case when no engrafted cells
were observed. Smits et al. [45] showed that injection of
human cardiac progenitor cells into infarcted mouse hearts
reduced cardiac remodeling 3 months after MI, despite the
fact that only 3-4% of the injected cells could be found in
the hearts at this time point. Together, these findings suggest
factors released by CSCs may mediate sustained beneficial
eﬀects, including angiogenesis and improved cardiomyocyte
survival. In this regard, CDCs have been shown to secrete a
number of growth factors [41] and microRNAs (miRNAs)
[46] that regulate intracellular signaling pathways in neigh-
boring cells. Culture media conditioned by ESCs or MSCs
were shown to improve myocardial function after ischemia
by reducing apoptosis and infarct size both in vitro and in
vivo [47–49]. Additional types of interstitial cells including
resident cardiac immune cells [50] may also contribute to
the secretion of cytokines and growth factors into their
microenvironment. Collectively, these studies indicate that
paracrine eﬀects of progenitor cells are a central mechanism
of cell therapy. This notion implies a dispensable role for cell
transplantation in therapeutic approaches for cardiac regen-
eration [17].
6. Microparticles and Exosomes
The demonstration of beneficial eﬀects of cell therapy despite
short-lived survival of the delivered cells, along with the
observed trophic eﬀects of culture media conditioned by
progenitor cells, suggests that secreted factors may be the
active component of cell therapy for cardiac regeneration, as
mentioned. Cells communicate with each other via released
molecules such as short peptides, proteins, nucleotides,
and lipids that bind to surface receptors on neighbor-
ing cells. In addition, eukaryotic cells communicate with
each other through the release of microparticles and exo-
somes in their extracellular environment. Microparticles are
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a heterogeneous population of spherical structures with a
diameter of 100–1000 nm, which are released by budding of
the plasma membrane (ectocytosis) as phospholipid vesicles
that express antigens specific of their parental cells [51]. Cir-
culating microparticles are increased in a number of disease
conditions, such as inflammatory and autoimmune diseases,
atherosclerosis, and cancer. Distinct from microparticles,
exosomes are membrane vesicles with a diameter of 40–
100 nm, formed by endocytosis, a process that involves the
sequestration of plasma membrane proteins within the exo-
somes. Exosomes are stored intracellularly in endosomal
compartments and are secreted when these multivesicular
structures fuse with the cell plasma membrane [52–55].
Exosomes display a broad spectrum of bioactive sub-
stances on their surface and carry a concentrated set of pro-
teins, lipids, and even nucleic acids that are taken up by
other cells and regulate their function [54–56]. Some exo-
somal membrane proteins are cleaved by proteases, and the
resulting fragments may act as ligands for cell surface recept-
ors in the target cell. Exosomes can also transfer exosomal
proteins and RNA nonselectively by fusing with target cells.
They are released by many cell types, including dendritic
cells, mast cells, B and T cells, platelets, neurons, tumor cells,
and MSCs.
Exosomes do not carry a random array of the intra-
cellular proteins but a specific set of proteins derived from
the plasma membrane, endocytic pathway, and the cytosol,
with only low amounts of proteins from other intracellular
compartments [53, 56]. Most exosomes contain tetraspanins
(CD81, CD63, and CD9) which play important roles in cell
penetration, invasion and fusion events, as well as multi-
vesicular body molecules (Alix, Tsg101, and clathrin), heat
shock protein 70 (HSP70), and Rabs that regulate exo-
some docking and membrane fusion [57]. Exosomes
also contain annexins, metabolic enzymes, ribosomal pro-
teins, signal transduction molecules, adhesion molecules,
ATPases, cytoskeletal and ubiquitin molecules, growth fac-
tors, cytokines, mRNA, and microRNA (miRNA) molecules
[53, 56, 58]. An exosome protein and RNA database (Exo-
Carta) is available at http://exocarta.ludwig.edu.au/. In addi-
tion to molecules shared by exosomes from multiple cell
types, exosomes carry specific proteins from their parental
cell type. It has been shown that mRNAs carried by exosomes
can be translated into proteins in the target cell, indica-
ting that exosomes can act as a vector of genetic information.
ESC-derived microvesicles have been shown to reprogram
hematopoietic progenitors by mRNA transfer and protein
delivery [59]. miRNA families can be selectively secreted into
the extracellular environment via exosomes [60]. Dendritic
cells release exosomes that are loaded with distinct sets of
miRNA dependent on the status of dendritic cell activation
[61]. These exosomes fuse with target cells, thereby transfer-
ring miRNAs that can repress mRNAs in these cells. Thus,
exosomes can mediate epigenetic eﬀects by transferring
specific miRNA molecules between cells.
Biological eﬀects of exosomes are cell type-specific,
reflecting their molecular composition. Recently, Sahoo et al.
[62] reported angiogenic eﬀects of exosomes derived from
human CD34+ BM stem cells in isolated endothelial cells
and inmurine models of vessel growth. These exosomes were
enriched with proangiogenicmiRNAs. By contrast, exosomes
derived from CD34-depleted BM cells lacked angiogenic
activities. In some of the in vitro and in vivo assays, the
exosomes from CD34+ cells appeared more potent than the
cells themselves, possibly as a result of the durability of the
exosome in culture. Vrijsen et al. [63] reported that exosomes
mediated the angiogenic activity of media conditioned by
human fetal cardiac progenitor cells in vitro. Timmers
et al. [49] showed that injection of conditioned medium
from ESC-derived MSCs reduced infarct size and improved
cardiac function in a pig model of ischemia/reperfusion, as
mentioned above. Exosomes within the conditionedmedium
were shown to contain the active component [64]. Lai
et al. [65] found that exosomes secreted by MSCs similarly
reduced myocardial ischemia/reperfusion injury in mice.
In extracardiac biological systems, exosomes were shown
to secrete synuclein that impacted neuronal survival [66], or
αB crystallin from polarized human retinal pigment epithe-
lium, which provided neuroprotection to adjacent cells [67],
just to mention a few examples. Altogether, exosomes act
as vectors for the intercellular exchange of biological signals
and information, which mediate cell activation, phenotypic
changes, and reprogramming of cell function. Exosomes and
microparticles represent a transcellular delivery system that
expands the limited transcriptome and proteome of recipient
cells and establishes a communication network among cells
[51].
7. Ultrastructural Evidence of Exosome
Secretion by Cardiac Progenitor Cells
Since CDCs deliver beneficial paracrine signals to injured
myocardium [41], and since exosomes have been identified
as the active component of the paracrine eﬀects of CD34+
HSCs [62] or MSCs [64, 65] in infarcted hearts, we investi-
gated whether CSCs and human CSs secrete exosomes.
Figure 3 shows transmission electron micrographs of pro-
genitor cells within a stem cell niche in a mouse adult heart,
as well as in an adult human CS in vitro. Progenitor cells exhi-
bit a similar ultrastructural appearance in the two con-
texts. Here, we also provide, for the first time, ultrastruc-
tural evidence of exosome and microvesicle secretion by
progenitor cells in mouse adult heart and in human CSs
(Figure 4). Microvesicles (≈200 nm diameter) have an elec-
tron-dense content. Exosomes can be distinguished from
microvesicles, apoptotic bodies, and other types of mem-
brane vesicles by size and ultrastructural appearance. Exo-
somes and microvesicles seems to be an important mech-
anism involved in the heterocellular communication in
the adult heart [68], especially between telocytes [69] and
resident progenitor cells [68, 70]. Some of us recently showed
that exosomes emerge from telocytes in the border zone of
myocardial infarction [71], consistent with a potential role
for this secreted component in neoangiogenesis; however, a
quantitative analysis was not performed.
Transmission electron micrographs suggesting exosome
uptake by cardiomyocytes in the adult mouse heart are
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Figure 3: Transmission electron micrographs showing a cardiac progenitor cell (CPC), characterized by a large nucleus and a thin
cytoplasmic rim, in adult mouse myocardium (a) and in an adult human CS in vitro (b).
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Figure 4: Transmission electron micrographs showing exosomes (≈75 nm diameter; Exo. (a)) and microvesicles (≈200 nm diameter; (b))
secreted by cardiac progenitor cells (CPC) in a human CS in vitro. Exosomes in adult mouse myocardium ((c)-(d); TC: telocyte; ESC:
extracellular space).
shown in Figure 5. Cardiomyocytes seem to encircle exo-
somes on their cell surfaces with thin cytoplasmic processes,
and exosomes are then incorporated into cardiomyocytes.
However, this preliminary observation needs to be analysed
in a larger number of samples. The molecular content and
functional activities of exosomes secreted by human CSCs
and CSs also remain to be characterized. An additional,
unanswered question relates to changes in exosome secretion
under normal and ischemic conditions.
8. Therapeutic Potential of Exosomes
Exosomes may circumvent many of the hurdles associated
with the use of replicating cells as a therapeutic agent,
such as the risk that replicating cells may increase in an
uncontrolled manner over time or exert persisting biological
activities regardless of the clinical needs of the patient. Also,
many autologous stem cell therapies require ex vivo cell
expansion, and therefore the preparation of the therapeutic
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Figure 5: Transmission electron micrographs showing exosomes in an adult mouse heart. (a) Exosomes (asterisks) located at the cell surface
of a cardiomyocyte (CM). The latter extends thin cytoplasmic processes (arrow) that encircle the exosome. Inset: higher magnification
view showing dense nanostructures (arrowheads) at the interface of the CM membrane and the membrane of the exosome, suggesting
involvement of molecular interactions in exosome uptake by CMs. (b) Exosomes (asterisks) encircled by cytoplasmic processes (arrow). (c)
Exosomes (asterisks) taken up by the CM within small, round cytoplasmic structures (arrows).
product may take several weeks. Moreover, autologous cells
from aged patients have limited regenerative potential [15],
whereas allogeneic cells are generally rejected by the immune
system (with the possible exception of MSCs, which mediate
immunomodulatory eﬀects [72]). A hypothetical advantage
of exosomes is that it might be possible to use allogeneic
cells from young, healthy individuals for their production,
although this remains to be demonstrated. Exosomes are
supposedly less immunogenic than their parental cells owing
to a lower content of membrane-derived proteins includ-
ing major histocompatibility complex (MHC) molecules.
However, this may depend on the parental cell type. Since
exosomes secreted by dendritic cells can transfer MHC class
II molecules and stimulate immune cells [73], they have
been tested in clinical trials in cancer patients [74–76]. CDCs
have been shown to express MHC class I but not class II
molecules [77], and therefore exosomes secreted by CDCs
can be assumed to lack MHC class II. If alloimmunogenicity
of exosomes secreted by CSs or CDCs turns out to be
negligible, it will be possible to develop “oﬀ-the-shelf” ther-
apies based on exosomes from young, healthy donors.
Obviously, cell-free products oﬀer a number of advantages
compared with cell transplantation. Cell-free products can
be standardized and tested in terms of dose and biological
activity. Exosomes could be stored without potentially toxic
cryopreservatives at −20◦C for 6 months with no loss in
their biochemical activities [64]. Importantly, exosomes have
been shown to protect their contents from degradation in
vivo [58, 78], thereby potentially preventing some of the
problems associated with small soluble molecules such as
cytokines, growth factors, transcription factors, and RNAs,
which are rapidly degraded. The durability of the exosomes
in culture permits to achieve high doses of exosomes through
collection from culture medium in which exosomes are sec-
reted over periods of time [62]. Scalable systems for exo-
some production to support large-scale, commercially viable
manufacturing processes have been described [64]. Exo-
somes therefore exhibit several attractive features as a ther-
apeutic agent. On the other hand, potential limitations
should be considered as well. For example, exosomes contain
a mixture of biologically active molecules, some of which
seem to have beneficial eﬀects, whereas others might have
detrimental (e.g., proinflammatory) eﬀects under certain
conditions. Whether exosomes will be superior to angiogenic
drugs or purified, recombinant growth factors and other
peptides within the context of cell-free approaches for tissue
regeneration remains to be seen.
9. Conclusions
CSs represent an in vitro model that recapitulates several
aspects of cell-cell interactions between CSCs and other
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cells in the heart. Exosomes may be a key mechanism by
which cardiac progenitors communicate with each other and
deliver paracrine signals to neighboring cells. Here, we pro-
vide, for the first time, ultrastructural evidence of exosome
secretion by progenitor cells in the adult mouse heart, as well
as in human CSs in vitro. Earlier studies have demonstrated
beneficial eﬀects of exosomes secreted by HSCs and MSCs in
animal models of MI. These studies suggest exosomes may
oﬀer major advantages as a cell-free therapeutic product for
cardiac regeneration.
Authors’ Contribution
L. Barile and M. Gherghiceanu contributed equally to this
work.
Acknowledgments
Support by the Swiss National Science Foundation, the
Cecilia Augusta Foundation, the METIS Foundation Sergio
Mantegazza, and the “Fondazione per la ricerca sulla trasfu-
sione e sui trapianti” (Lugano) is gratefully acknowledged.
References
[1] D. Orlic, J. Kajstura, S. Chimenti et al., “Bone marrow cells
regenerate infarcted myocardium,” Nature, vol. 410, no. 6829,
pp. 701–705, 2001.
[2] L. B. Balsam, A. J. Wagers, J. L. Christensen, T. Kofidis, I. L.
Weissmann, and R. C. Robbins, “Haematopoietic stem cells
adopt mature haematopoietic fates in ischaemic myocard-
ium,” Nature, vol. 428, no. 6983, pp. 668–673, 2004.
[3] C. E. Murry, M. H. Soonpaa, H. Reinecke et al., “Haematopoi-
etic stem cells do not transdiﬀerentiate into cardiac myocytes
in myocardial infarcts,” Nature, vol. 428, no. 6983, pp. 664–
668, 2004.
[4] C. Stamm, B. Westphal, H. D. Kleine et al., “Autologous bone-
marrow stem-cell transplantation for myocardial regenera-
tion,” The Lancet, vol. 361, no. 9351, pp. 45–46, 2003.
[5] K. C. Wollert, G. P. Meyer, J. Lotz et al., “Intracoronary autol-
ogous bone-marrow cell transfer after myocardial infarction:
the BOOST randomised controlled clinical trial,” The Lancet,
vol. 364, no. 9429, pp. 141–148, 2004.
[6] V. Scha¨chinger, S. Erbs, A. Elsa¨sser et al., “Intracoronary
bone marrow-derived progenitor cells in acute myocardial
infarction,” The New England Journal of Medicine, vol. 355, no.
12, pp. 1210–1221, 2006.
[7] B. Assmus, J. Honold, V. Scha¨chinger et al., “Transcoronary
transplantation of progenitor cells after myocardial infarc-
tion,” The New England Journal of Medicine, vol. 355, no. 12,
pp. 1222–1232, 2006.
[8] S. Janssens, C. Dubois, J. Bogaert et al., “Autologous bone
marrow-derived stem-cell transfer in patients with ST-
segment elevation myocardial infarction: double-blind, ran-
domised controlled trial,” The Lancet, vol. 367, no. 9505, pp.
113–121, 2006.
[9] K. Lunde, S. Solheim, S. Aakhus et al., “Intracoronary injec-
tion of mononuclear bone marrow cells in acute myocardial
infarction,” The New England Journal of Medicine, vol. 355, no.
12, pp. 1199–1209, 2006.
[10] E. Forte, I. Chimenti, L. Barile et al., “Cardiac cell therapy: the
next (re)generation,” Stem Cell Reviews and Reports, vol. 7, pp.
1018–1030, 2011.
[11] E. Chavakis, M. Koyanagi, and S. Dimmeler, “Enhancing the
outcome of cell therapy for cardiac repair: progress from
bench to bedside and back,” Circulation, vol. 121, no. 2, pp.
325–335, 2010.
[12] A. Abdel-Latif, R. Bolli, I. M. Tleyjeh et al., “Adult bone
marrow-derived cells for cardiac repair: a systematic review
and meta-analysis,” Archives of Internal Medicine, vol. 167, no.
10, pp. 989–997, 2007.
[13] K. C. Wollert and H. Drexler, “Cell therapy for the treatment
of coronary heart disease: a critical appraisal,” Nature Reviews
Cardiology, vol. 7, no. 4, pp. 204–215, 2010.
[14] D. M. Leistner, U. Fischer-Rasokat, J. Honold et al., “Trans-
plantation of progenitor cells and regeneration enhancement
in acute myocardial infarction (TOPCARE-AMI): final 5-year
results suggest long-term safety and eﬃcacy,” Clinical Research
in Cardiology, vol. 100, no. 10, pp. 925–934, 2011.
[15] S. Dimmeler and A. Leri, “Aging and disease as modifiers of
eﬃcacy of cell therapy,” Circulation Research, vol. 102, no. 11,
pp. 1319–1330, 2008.
[16] H. Ebelt, M. Jungblut, Y. Zhang et al., “Cellular cardiomy-
oplasty: improvement of left ventricular function correlates
with the release of cardioactive cytokines,” Stem Cells, vol. 25,
no. 1, pp. 236–244, 2007.
[17] K. R. Vrijsena, S. A. J. Chamuleaua, W. A. Noorta, P. A.
Doevendansa, and J. P. G. Sluijtera, “Stem cell therapy for end-
stage heart failure: indispensable role for the cell?” Current
Opinion in Organ Transplantation, vol. 14, no. 5, pp. 560–565,
2009.
[18] M. Gnecchi, Z. Zhang, A. Ni, and V. J. Dzau, “Paracrine mech-
anisms in adult stem cell signaling and therapy,” Circulation
Research, vol. 103, no. 11, pp. 1204–1219, 2008.
[19] S. Ausoni and S. Sartore, “The cardiovascular unit as a
dynamic player in disease and regeneration,” Trends in Molec-
ular Medicine, vol. 15, no. 12, pp. 543–552, 2009.
[20] K. Urbanek, D. Cesselli, M. Rota et al., “Stem cell niches in
the adult mouse heart,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 103, no. 24, pp.
9226–9231, 2006.
[21] A. P. Beltrami, L. Barlucchi, D. Torella et al., “Adult cardiac
stem cells are multipotent and support myocardial regenera-
tion,” Cell, vol. 114, no. 6, pp. 763–776, 2003.
[22] H. Oh, S. B. Bradfute, T. D. Gallardo et al., “Cardiac progenitor
cells from adult myocardium: homing, diﬀerentiation, and
fusion after infarction,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 100, no. 21, pp.
12313–12318, 2003.
[23] H. C. Ott, T. S. Matthiesen, J. Brechtken et al., “The adult
human heart as a source for stem cells: repair strategies
with embryonic-like progenitor cells,” Nature Clinical Practice
Cardiovascular Medicine, vol. 4, supplement 1, pp. S27–S39,
2007.
[24] C. Bearzi, M. Rota, T. Hosoda et al., “Human cardiac stem
cells,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 104, no. 35, pp. 14068–14073,
2007.
[25] R. R. Smith, L. Barile, H. C. Cho et al., “Regenerative potential
of cardiosphere-derived cells expanded from percutaneous
endomyocardial biopsy specimens,” Circulation, vol. 115, no.
7, pp. 896–908, 2007.
[26] A. Linke, P. Mu¨ller, D. Nurzynska et al., “Stem cells in the
dog heart are self-renewing, clonogenic, and multipotent and
regenerate infarcted myocardium, improving cardiac func-
tion,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 102, no. 25, pp. 8966–8971, 2005.
Journal of Biomedicine and Biotechnology 9
[27] A. M. Smits, P. van Vliet, C. H. Metz et al., “Human cardio-
myocyte progenitor cells diﬀerentiate into functional mature
cardiomyocytes: an in vitro model for studying human cardiac
physiology and pathophysiology,” Nature Protocols, vol. 4, no.
2, pp. 232–243, 2009.
[28] L. Barile, I. Chimenti, R. Gaetani et al., “Cardiac stem cells: iso-
lation, expansion and experimental use for myocardial regen-
eration,” Nature Clinical Practice Cardiovascular Medicine, vol.
4, supplement 1, pp. S9–S14, 2007.
[29] L. Barile, E. Messina, A. Giacomello, and E. Marba´n, “Endoge-
nous cardiac stem cells,” Progress in Cardiovascular Diseases,
vol. 50, no. 1, pp. 31–48, 2007.
[30] G. M. Ellison, V. Galuppo, C. Vicinanza et al., “Cardiac stem
and progenitor cell identification: diﬀerent markers for the
same cell?” Frontiers in Bioscience, vol. 2, pp. 641–652, 2010.
[31] L. Barile, F. Cerisoli, G. Frati et al., “Bonemarrow-derived cells
can acquire cardiac stem cells properties in damaged heart,”
Journal of Cellular and Molecular Medicine, vol. 15, no. 1, pp.
63–71, 2011.
[32] S. S. Fazel, L. Chen, D. Angoulvant et al., “Activation of c-
kit is necessary for mobilization of reparative bone marrow
progenitor cells in response to cardiac injury,” The FASEB
Journal, vol. 22, no. 3, pp. 930–940, 2008.
[33] L. W. van Laake, L. Qian, P. Cheng et al., “Reporter-based iso-
lation of induced pluripotent stem cell-and embryonic stem
cell-derived cardiac progenitors reveals limited gene expres-
sion variance,” Circulation Research, vol. 107, no. 3, pp. 340–
347, 2010.
[34] Y. Yoshida and S. Yamanaka, “IPS cells: a source of cardiac
regeneration,” Journal of Molecular and Cellular Cardiology,
vol. 50, no. 2, pp. 327–332, 2011.
[35] B. A. Reynolds and S. Weiss, “Generation of neurons and
astrocytes from isolated cells of the adult mammalian central
nervous system,” Science, vol. 255, no. 5052, pp. 1707–1710,
1992.
[36] E. Pastrana, V. Silva-Vargas, and F. Doetsch, “Eyes wide open:
a critical review of sphere-formation as an assay for stem cells,”
Cell Stem Cell, vol. 8, no. 5, pp. 486–498, 2011.
[37] E. Messina, L. De Angelis, G. Frati et al., “Isolation and expan-
sion of adult cardiac stem cells from human and murine
heart,” Circulation Research, vol. 95, no. 9, pp. 911–921, 2004.
[38] T. S. Li, K. Cheng, S. T. Lee et al., “Cardiospheres recapitulate a
niche-like microenvironment rich in stemness and cell-matrix
interactions, rationalizing their enhanced functional potency
for myocardial repair,” Stem Cells, vol. 28, no. 11, pp. 2088–
2098, 2010.
[39] D. R. Davis, Y. Zhang, R. R. Smith et al., “Validation of the
cardiosphere method to culture cardiac progenitor cells from
myocardial tissue,” PLoS ONE, vol. 4, no. 9, Article ID e7195,
2009.
[40] D. C. Andersen, P. Andersen, M. Schneider, H. B. Jensen, and
S. P. Sheikh, “Murine “cardiospheres” are not a source of stem
cells with cardiomyogenic potential,” Stem Cells, vol. 27, no. 7,
pp. 1571–1581, 2009.
[41] I. Chimenti, R. R. Smith, T. S. Li et al., “Relative roles of direct
regeneration versus paracrine eﬀects of human cardiosphere-
derived cells transplanted into infarcted mice,” Circulation
Research, vol. 106, no. 5, pp. 971–980, 2010.
[42] R. Bolli, A. R. Chugh, D. D’Amario et al., “Cardiac stem cells
in patients with ischaemic cardiomyopathy (SCIPIO): initial
results of a randomised phase 1 trial,” The Lancet, vol. 378, no.
9806, pp. 1847–1857, 2011.
[43] R. R. Makkar, R. R. Smith, K. Cheng et al., “Intracoro-
nary cardiosphere-derived cells for heart regeneration after
myocardial infarction (CADUCEUS): a prospective, ran-
domised phase 1 trial,” The Lancet, vol. 379, no. 9819, pp. 895–
904, 2012.
[44] X. L. Tang, G. Rokosh, S. K. Sanganalmath et al., “Intracoro-
nary administration of cardiac progenitor cells alleviates left
ventricular dysfunction in rats with a 30-day-old infarction,”
Circulation, vol. 121, no. 2, pp. 293–305, 2010.
[45] A. M. Smits, L. W. Van Laake, K. Den Ouden et al., “Human
cardiomyocyte progenitor cell transplantation preserves long-
term function of the infarcted mouse myocardium,” Cardio-
vascular Research, vol. 83, no. 3, pp. 527–535, 2009.
[46] E. Kizana, E. Cingolani, and E. Marba´n, “Non-cell-auto-
nomous eﬀects of vector-expressed regulatory RNAs in mam-
malian heart cells,” Gene Therapy, vol. 16, no. 9, pp. 1163–
1168, 2009.
[47] P. R. Crisostomo, A. M. Abarbanell, M. Wang, T. Lahm, Y.
Wang, and D. R. Meldrum, “Embryonic stem cells attenuate
myocardial dysfunction and inflammation after surgical global
ischemia via paracrine actions,” American Journal of Physiol-
ogy, vol. 295, no. 4, pp. H1726–H1735, 2008.
[48] M. Gnecchi, H. He, N. Noiseux et al., “Evidence supporting
paracrine hypothesis for Akt-modified mesenchymal stem
cell-mediated cardiac protection and functional improve-
ment,” The FASEB Journal, vol. 20, no. 6, pp. 661–669, 2006.
[49] L. Timmers, S. K. Lim, F. Arslan et al., “Reduction of myo-
cardial infarct size by human mesenchymal stem cell condi-
tioned medium,” Stem Cell Research, vol. 1, no. 2, pp. 129–137,
2008.
[50] F. Bo¨nner, N. Borg, S. Burghoﬀ, and J. Schrader, “Resident
cardiac immune cells and expression of the ectonucleotidase
enzymes CD39 and CD73 after ischemic injury,” PLoS One,
vol. 7, Article ID e34730, 2012.
[51] S. F. Mause and C. Weber, “Microparticles: protagonists of a
novel communication network for intercellular information
exchange,”Circulation Research, vol. 107, no. 9, pp. 1047–1057,
2010.
[52] C. The´ry, “Exosomes: secreted vesicles and intercellular com-
munications,” F1000 Biology Reports, vol. 3, no. 1, article 15,
2011.
[53] C. The´ry, S. Amigorena, G. Raposo, and A. Clayton, “Isolation
and characterization of exosomes from cell culture super-
natants and biological fluids,” Current Protocols in Cell Biology,
vol. 3, article 22, 2006.
[54] S. Mathivanan, H. Ji, and R. J. Simpson, “Exosomes: extra-
cellular organelles important in intercellular communication,”
Journal of Proteomics, vol. 73, no. 10, pp. 1907–1920, 2010.
[55] P. J. Quesenberry and J. M. Aliotta, “Cellular phenotype
switching andmicrovesicles,”Advanced Drug Delivery Reviews,
vol. 62, no. 12, pp. 1141–1148, 2010.
[56] S. Mathivanan and R. J. Simpson, “ExoCarta: a compendium
of exosomal proteins and RNA,” Proteomics, vol. 9, no. 21, pp.
4997–5000, 2009.
[57] M. Ostrowski, N. B. Carmo, S. Krumeich et al., “Rab27a
and Rab27b control diﬀerent steps of the exosome secretion
pathway,” Nature cell biology, vol. 12, no. 1, pp. 19–3013, 2010.
[58] H. Valadi, K. Ekstro¨m, A. Bossios, M. Sjo¨strand, J. J. Lee,
and J. O. Lo¨tvall, “Exosome-mediated transfer of mRNAs and
microRNAs is a novel mechanism of genetic exchange between
cells,” Nature Cell Biology, vol. 9, no. 6, pp. 654–659, 2007.
[59] J. Ratajczak, K. Miekus, M. Kucia et al., “Embryonic stem cell-
derived microvesicles reprogram hematopoietic progenitors:
evidence for horizontal transfer of mRNA and protein deliv-
ery,” Leukemia, vol. 20, no. 5, pp. 847–856, 2006.
10 Journal of Biomedicine and Biotechnology
[60] K. Ohshima, K. Inoue, A. Fujiwara et al., “Let-7 microRNA
family Is selectively secreted into the extracellular environ-
ment via exosomes in a metastatic gastric cancer cell line,”
PLoS ONE, vol. 5, no. 10, Article ID e13247, 2010.
[61] A. Montecalvo, A. T. Larregina, W. J. Shufesky et al., “Mech-
anism of transfer of functional microRNAs between mouse
dendritic cells via exosomes,” Blood, vol. 119, no. 3, pp. 756–
766, 2012.
[62] S. Sahoo, E. Klychko, T. Thorne et al., “Exosomes from human
CD34+ stem cells mediate their proangiogenic paracrine acti-
vity,” Circulation Research, vol. 109, pp. 724–728, 2011.
[63] K. R. Vrijsen, J. P. G. Sluijter, M. W. L. Schuchardt et al.,
“Cardiomyocyte progenitor cell-derived exosomes stimulate
migration of endothelial cells,” Journal of Cellular and Molecu-
lar Medicine, vol. 14, no. 5, pp. 1064–1070, 2010.
[64] R. C. Lai, T. S. Chen, and S. K. Lim, “Mesenchymal stem cell
exosome: a novel stem cell-based therapy for cardiovascular
disease,” Regenerative Medicine, vol. 6, no. 4, pp. 481–492,
2011.
[65] R. C. Lai, F. Arslan, M. M. Lee et al., “Exosome secreted by
MSC reduces myocardial ischemia/reperfusion injury,” Stem
Cell Research, vol. 4, no. 3, pp. 214–222, 2010.
[66] E. Emmanouilidou, K. Melachroinou, T. Roumeliotis et al.,
“Cell-produced α-synuclein is secreted in a calcium-depend-
ent manner by exosomes and impacts neuronal survival,”
Journal of Neuroscience, vol. 30, no. 20, pp. 6838–6851, 2010.
[67] P. G. Sreekumar, R. Kannan, M. Kitamura et al., “αB crystallin
is apically secreted within exosomes by polarized human
retinal pigment epithelium and provides neuroprotection to
adjacent cells,” PLoS ONE, vol. 5, no. 10, Article ID e12578,
2010.
[68] M. Gherghiceanu and L. M. Popescu, “Cardiac telocytes—
their junctions and functional implications,” Cell Tissue
Research, vol. 348, no. 2, pp. 265–279, 2012.
[69] L.M. Popescu andM. S. Faussone-Pellegrini, “TELOCYTES—
a case of serendipity: the winding way from Interstitial Cells
of Cajal (ICC), via Interstitial Cajal-Like Cells (ICLC) to
TELOCYTES,” Journal of Cellular and Molecular Medicine, vol.
14, no. 4, pp. 729–740, 2010.
[70] M. Gherghiceanu and L. M. Popescu, “Cardiomyocyte precur-
sors and telocytes in epicardial stem cell niche: electronmicro-
scope images,” Journal of Cellular and Molecular Medicine, vol.
14, no. 4, pp. 871–877, 2010.
[71] C. G. Manole, V. Cismas¸iu, M. Gherghiceanu, and L. M.
Popescu, “Experimental acute myocardial infarction: telocytes
involvement in neo-angiogenesis,” Journal of Cellular and
Molecular Medicine, vol. 15, no. 11, pp. 2284–2296, 2011.
[72] H. Yagi, A. Soto-Gutierrez, B. Parekkadan et al., “Mesenchy-
mal stem cells: mechanisms of immunomodulation and hom-
ing,” Cell Transplantation, vol. 19, no. 6-7, pp. 667–679, 2010.
[73] L. Zitvogel, A. Regnault, A. Lozier et al., “Eradication of
established murine tumors using a novel cell-free vaccine:
dendritic cell-derived exosomes,” Nature Medicine, vol. 4, no.
5, pp. 594–600, 1998.
[74] B. Escudier, T. Dorval, N. Chaput et al., “Vaccination of meta-
static melanoma patients with autologous dendritic cell (DC)
derived-exosomes: results of the first phase 1 clinical trial,”
Journal of Translational Medicine, vol. 3, article 10, 2005.
[75] M. A. Morse, J. Garst, T. Osada et al., “A phase I study of dexo-
some immunotherapy in patients with advanced non-small
cell lung cancer,” Journal of Translational Medicine, vol. 3,
article 9, 2005.
[76] S. Dai, D. Wei, Z. Wu et al., “Phase I clinical trial of auto-
logous ascites-derived exosomes combined with GM-CSF for
colorectal cancer,” Molecular Therapy, vol. 16, no. 4, pp. 782–
790, 2008.
[77] K. Malliaras, T. S. Li, D. Luthringer et al., “Safety and eﬃcacy
of allogeneic cell therapy in infarcted rats transplanted with
mismatched cardiosphere-derived cells,” Circulation, vol. 125,
pp. 100–112, 2012.
[78] N. Chaput and C. The´ry, “Exosomes: immune properties
and potential clinical implementations,” Seminars in Immuno-
pathology, vol. 33, no. 5, pp. 419–440, 2011.
